TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 4, Issue 3, 2017
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
DESIGN AND EVALUATION OF AZATHIOPRINE NANOPARTICLES
Author
Umasankar K* and Jayachandra Reddy P
Email
umasankar73@gmail.com
keyword
Evaluation, Azathioprine, Nanoparticles, Design.
Abstract
Studies show nanoparticles containing a coat of PEG not only have a prolonged half-life in the blood compartment but also be able to selectively extravagates in pathological sites such as tumors or inflamed regions with a leaky vasculature. As a result, such long-circulating nanoparticles have increased the potential to directly target tumors located outside MPS-rich regions. The size of the colloidal carriers as well as their surface characteristics are the critical to the biological fate of nanoparticles. A size less than 100 nm and a hydrophilic surface are essential in achieving the reduction of opsonisation reactions and subsequent clearance by macrophages. Coating conventional nanoparticles with surfactants or PEG to obtain a long-circulating carrier has now been used as a standard strategy for drug targeting in vivo. Significant advances in biotechnology and biochemistry have led to the discovery of a large number of bioactive molecules and vaccines based on peptides and proteins. Development of suitable carriers remains a challenge due to the fact that bioavailability of these molecules is limited by the epithelial barriers of the gastrointestinal tract and their susceptibility to gastrointestinal degradation by digestive enzymes. Polymeric nanoparticles allow encapsulation of bioactive molecules and protect them against enzymatic and hydrolytic degradation. For instance, it has been found that insulin-loaded nanoparticles have preserved insulin activity and produced blood glucose reduction in diabetic rats for up to 14 days following the oral administration.
Download Broucher
Back to Top >>>>